Sermorelin vs CJC-1295 vs tesamorelin: how to choose a GHRH analog

TL;DR

• Same receptor, same job - all three are GHRH analogs; duration and depth of evidence are the only things separating them.
• Sermorelin is the short-acting original - a brief physiologic pulse, historical Phase II/III data, once approved as Geref, now compounded.
• CJC-1295 is the tunable one - short and pulsatile without DAC; with DAC it binds albumin for a 6–8 day half-life and a sustained GH "bleed."
• Tesamorelin is the evidence leader - the only FDA-approved one, on Phase III RCTs showing visceral-fat reduction and IGF-1 normalization.
• All three are usually paired with a GHRP such as ipamorelin, because separate receptors produce a synergistic GH release.
• Monitoring does not change with the molecule - baseline and follow-up IGF-1 and glucose, plus the GH/IGF-1 cancer-history screen.

All three are GHRH analogs - they trigger your natural GH pulse the same way. What separates them is how long they last and how much evidence stands behind them. That's the whole decision. Here's the honest comparison.

Educational content, not medical advice. No doses or protocols appear; GH-axis use is physician-directed. Of the three, only tesamorelin is FDA-approved, and only for one specific condition.

---

Once you know that GHRH analogs are the "pulse trigger" family - they mimic the hypothalamic signal that starts each GH pulse - the three most common ones stop looking interchangeable. Sermorelin, CJC-1295 and tesamorelin do the same job through the same receptor; they differ on duration and evidence. This is the map for choosing between them (and all three are typically paired with a GHRP like ipamorelin for synergy).

The three at a glance

Sermorelin - the short-acting original

Sermorelin is the oldest and shortest-acting of the three: a truncated GHRH analog that produces a brief, physiologic pulse close to how your body naturally signals GH. It has historical Phase II/III data in growth-hormone-deficient adults and was once FDA-approved (as Geref) before the brand was discontinued; today it's typically accessed through compounding. Its appeal is exactly that gentleness - a short pulse that respects the body's natural rhythm - which is also its limitation for anyone chasing a bigger, longer signal.

CJC-1295 - the tunable one (DAC vs no DAC)

CJC-1295 is where duration becomes a design choice, and the DAC decision is the whole story:

• Without DAC (often "Mod GRF 1-29") it's short-acting, giving a pulsatile release that mimics physiology.
• With DAC it binds albumin and stretches its half-life to 6–8 days, producing a sustained GH "bleed" and far less frequent dosing.

The trade-off is physiologic fidelity vs convenience: pulsatile is closer to natural signaling, while the DAC version's continuous elevation is less physiologic and raises the steady-IGF-1 questions that come with tonic GH exposure. Human evidence for CJC-1295 specifically is limited.

Tesamorelin - the evidence leader

Tesamorelin is the only one of the three that's FDA-approved - and it earned that with the strongest data: Phase III randomized controlled trials in HIV-associated lipodystrophy showing visceral-fat reduction and IGF-1 normalization. That approval is narrow (a specific condition), so the muscle/anti-aging uses people ask about are off-label extrapolations - but among GHRH analogs, tesamorelin is the one with real trial weight behind it. Full tesamorelin breakdown here. (It's also WADA-banned for athletes.)

How each pairs with a GHRP - and who each suits

All three are commonly combined with a GHRP such as ipamorelin, because a GHRH analog + a GHRP hit separate receptors and produce a synergistic GH release. As a rough orientation (not a protocol):

• Sermorelin suits someone wanting the gentlest, most physiologic support and comfortable with short-acting dosing.
• CJC-1295 suits someone prioritizing convenience or steadier elevation - with the DAC-vs-no-DAC choice made deliberately with a clinician.
• Tesamorelin suits someone who values the strongest evidence base and a visceral-fat-focused goal.

The honest truth is that the "right" one is a clinician-and-labs decision, not a leaderboard.

Cost, access, and monitoring

Tesamorelin, as an approved daily drug, generally sits at the higher-cost, more-documented end; sermorelin and CJC-1295 are usually compounded or research-grade, cheaper but with the sourcing and verification risks that come with that. Whichever the choice, the monitoring is the same: baseline and follow-up bloodwork (IGF-1, glucose), and screening for the GH/IGF-1 cancer-history caution. Sourcing you can verify matters more than the specific molecule.

The bottom line

Sermorelin, CJC-1295 and tesamorelin are the same kind of tool at three settings: short and physiologic, tunable-and-convenient, and evidence-backed-but-narrowly-approved. Tesamorelin wins on data; sermorelin on gentleness; CJC-1295 on flexibility. None is a shortcut, all belong in supervised care, and each is usually paired with a GHRP rather than used alone.

Not sure which analog fits? That's the point of a consult, not a checkout page. Vivre Labs matches the GHRH analog to your goals and labs - sermorelin, CJC-1295 or tesamorelin, typically alongside ipamorelin - with monitoring built in. Reserve your place or book a consult - Telegram · see the V-G1 Build GH-axis protocol. vivrelabs.com

Frequently asked questions

Which GHRH peptide is strongest? "Strongest" depends on what you mean. Tesamorelin has the strongest evidence (Phase III RCTs). CJC-1295 with DAC produces the most sustained GH elevation. Sermorelin is the gentlest and most physiologic.

Which is safest? They share the class's GH/IGF-1 and blood-sugar cautions. Tesamorelin is the most studied and the only approved one; the others have thinner human data and (if research-grade) sourcing risk. All warrant screening and monitoring.

Do I need a doctor for these? Yes - meaningfully. Tesamorelin is prescription-only; the others carry the same GH/IGF-1 cautions and are best used with baseline and follow-up labs. Self-sourcing skips exactly the screening that keeps them safe.

Related reading

• How growth-hormone peptides work - the GH/IGF-1 axis · Recombinant GH versus secretagogues, head to head · Ipamorelin · CJC-1295 with or without DAC · Tesamorelin explained · Sermorelin: the original GHRH analogue
• Part of The Complete Guide to Growth-Hormone Peptides

---

Educational content, not medical advice. Of these, only tesamorelin is FDA-approved (for HIV lipodystrophy); sermorelin and CJC-1295 are not approved for anti-aging/muscle use. GH-axis compounds raise GH/IGF-1 and can affect insulin sensitivity; physician-directed use with monitoring. WADA-prohibited. SEA-market claims are subject to MAB requirements.

References

• GHRH-receptor agonism (Gs/cAMP/PKA) shared by sermorelin, CJC-1295, tesamorelin. · CJC-1295 + DAC albumin binding, 6–8 day half-life. · Tesamorelin Phase III RCT data (HIV lipodystrophy): visceral fat, IGF-1. · Sermorelin historical Phase II/III (GH-deficient adults). · WADA Prohibited List (S2).